Corvus Pharmaceuticals, Inc.
CRVS
$13.33
-$0.60-4.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -9.97% | 62.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.71% | 21.77% | |||
| Operating Income | -29.71% | -21.77% | |||
| Income Before Tax | -31.16% | -11.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -31.16% | -11.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -31.16% | -11.13% | |||
| EBIT | -29.71% | -21.77% | |||
| EBITDA | -29.73% | -21.79% | |||
| EPS Basic | -27.81% | -2.42% | |||
| Normalized Basic EPS | -27.76% | -2.48% | |||
| EPS Diluted | -27.81% | -2.42% | |||
| Normalized Diluted EPS | -27.76% | -2.48% | |||
| Average Basic Shares Outstanding | 2.63% | 8.48% | |||
| Average Diluted Shares Outstanding | 2.63% | 8.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||